Myeloma Minimal Residual Disease and Surrogacy-Reply

Affiliations

¹ Dana-Farber Cancer Institute, Boston, Massachusetts.
² Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, England.

Comment

Nikhil Munshi et al. JAMA Oncol. 2017.

. 2017 Aug 1;3(8):1136-1137.

doi: 10.1001/jamaoncol.2017.0404.

¹ Dana-Farber Cancer Institute, Boston, Massachusetts.
² Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, England.

No abstract available

Comment on

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM. Munshi NC, et al. JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160. JAMA Oncol. 2017. PMID: 27632282 Free PMC article.
Myeloma Minimal Residual Disease and Surrogacy.
Little RF, McShane LM, Freidlin B. Little RF, et al. JAMA Oncol. 2017 Aug 1;3(8):1136. doi: 10.1001/jamaoncol.2016.5660. JAMA Oncol. 2017. PMID: 28494064 No abstract available.